US20030203032A1 - Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease - Google Patents
Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease Download PDFInfo
- Publication number
- US20030203032A1 US20030203032A1 US10/132,843 US13284302A US2003203032A1 US 20030203032 A1 US20030203032 A1 US 20030203032A1 US 13284302 A US13284302 A US 13284302A US 2003203032 A1 US2003203032 A1 US 2003203032A1
- Authority
- US
- United States
- Prior art keywords
- hydrogel
- growth factor
- wound
- ppb
- healing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003102 growth factor Substances 0.000 title claims abstract description 75
- 208000027418 Wounds and injury Diseases 0.000 title abstract description 45
- 206010052428 Wound Diseases 0.000 title abstract description 44
- 230000035876 healing Effects 0.000 title abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 7
- 206010061218 Inflammation Diseases 0.000 title description 3
- 230000004054 inflammatory process Effects 0.000 title description 3
- 230000002265 prevention Effects 0.000 title description 3
- 201000010099 disease Diseases 0.000 title description 2
- 239000000017 hydrogel Substances 0.000 claims abstract description 118
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 36
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract description 35
- 101800003838 Epidermal growth factor Proteins 0.000 claims abstract description 35
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract description 35
- 238000012377 drug delivery Methods 0.000 claims abstract description 15
- 239000007864 aqueous solution Substances 0.000 claims abstract description 7
- 210000001519 tissue Anatomy 0.000 claims description 24
- 210000000981 epithelium Anatomy 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 12
- 230000004438 eyesight Effects 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- NXBDLTJZZIKTKL-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoic acid 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(O)=O.C=CN1CCCC1=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C NXBDLTJZZIKTKL-UHFFFAOYSA-N 0.000 claims description 7
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 6
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 6
- 230000003511 endothelial effect Effects 0.000 claims description 6
- 229920001616 Polymacon Polymers 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 229920000831 ionic polymer Polymers 0.000 claims description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- UACSZOWTRIJIFU-UHFFFAOYSA-N hydroxymethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCO UACSZOWTRIJIFU-UHFFFAOYSA-N 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 230000001681 protective effect Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- NLAIHECABDOZBR-UHFFFAOYSA-M sodium 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O.CC(=C)C(=O)OCCO.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C NLAIHECABDOZBR-UHFFFAOYSA-M 0.000 claims description 3
- 229920006029 tetra-polymer Polymers 0.000 claims description 3
- UAXOELSVPTZZQG-UHFFFAOYSA-N trimethyl acrylic acid Chemical compound CC(C)=C(C)C(O)=O UAXOELSVPTZZQG-UHFFFAOYSA-N 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 16
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 238000012546 transfer Methods 0.000 abstract description 5
- 210000004087 cornea Anatomy 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- 238000001356 surgical procedure Methods 0.000 description 9
- 239000010410 layer Substances 0.000 description 8
- 238000002791 soaking Methods 0.000 description 8
- 230000029663 wound healing Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000006196 drop Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 208000001491 myopia Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000004379 myopia Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- GNTAAQBKCCJXGF-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one methyl 2-methylprop-2-enoate 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate prop-2-enyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.C=CN1CCCC1=O.CC(=C)C(=O)OCC=C.CC(=C)C(=O)OCCOC(=O)C(C)=C GNTAAQBKCCJXGF-UHFFFAOYSA-N 0.000 description 2
- 206010020675 Hypermetropia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 201000009310 astigmatism Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004305 hyperopia Effects 0.000 description 2
- 201000006318 hyperopia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
Definitions
- the invention relates to the fields of hydrogels, drug delivery systems, and wound healing.
- Corneal wounds caused by injury, disease, or surgery represent a serious medical condition that may lead to loss of sight.
- persistent epithelial defects can lead to stromal melting, which causes serious visual dysfunction.
- Wound healing of corneal mucosal tissue has taken on increased importance with the advent of laser corrective surgery to re-establish normal vision for people who do not wish to wear contact lenses or spectacles.
- laser surgical methods are used to correct vision for nearsightedness (myopia), farsightedness (hyperopia), and astigmatism.
- the methods include laser in situ keratomileusis (LASIK), laser epithelial keratomileusis (LASEK), and photo-refractive keratectomy (PRK).
- LASIK refers to the use of a laser to reshape the cornea without invading the adjacent cell layers.
- a microkeratome is used to separate the surface layers of the cornea and create a corneal flap (160-180 microns deep). This flap stays attached to the rest of the cornea and is folded back on one side to expose the stroma of the cornea.
- the laser delivers pulses of ultraviolet light onto the inner cornea (stroma). Each pulse removes a microscopic layer of the inner cornea to reshape the surface of the cornea.
- the procedure flattens the cornea.
- the procedure increases the curvature of the cornea.
- corneal flap is replaced where it bonds without the need for stitches.
- the anterior layers of the cornea epidermal, Bowman's Layer
- eye drops which are used to prevent infection & swelling, with varying degrees of success.
- patients are able to see clearly without depending on glasses or contacts.
- the surgeon removes the epithelium (the anterior layer of the cornea or Bowman's Layer), which is a thin layer of protective skin that covers the cornea.
- This layer can be removed with an excimer laser or a brush.
- the patient stares at a fixation light. In less than a minute, the laser removes the proper amount of tissue while it reshapes the surface of the cornea.
- the excimer laser delivers pulses of ultraviolet light into the cornea. This exposure to laser radiation reduces or eliminates nearsightedness by flattening the central cornea and relocating the focal point of the lens onto the retina rather than in front of it, which produces sharper vision.
- a bandage contact lens is placed on the eye for 2-3 days.
- the purpose of the contact lens given to PRK patients post-surgically is to protect the leading edge of the corneal epithelium that is regenerating along the surface of the eye, post-surgery. As patients blink, the newer leading edge of the epithelium may be removed. As a result, recovery takes longer and there is an increased risk of infection.
- LASEK is similar to PRK but the epithelium is detached by using an alcohol solution that weakens the epithelium and allows it to fold back into a flap. A laser is then used to re-shape the cornea and correct vision acuity.
- the present invention features hydrogel drug delivery systems and methods of producing and using such systems for the treatment of wounds.
- the systems are based on a hydrogel into which a growth factor, e.g., epidermal growth factor (EGF), is passively transferred from a dilute aqueous solution.
- a growth factor e.g., epidermal growth factor (EGF)
- EGF epidermal growth factor
- the amount of growth factor absorbed into the hydrogel is low, e.g., ⁇ 350 ppb, but this amount surprisingly is effective in producing a therapeutic effect likely because the delivery system is localized and provides a sustained release of the factor.
- the systems are applicable to ocular wounds, especially after vision correcting surgery, as well as other wound treatments.
- the invention features a polymeric hydrogel that comprises a substantially pure growth factor, e.g., epidermal growth factor, platelet derived growth factor, hepatocytic growth factor, or combinations thereof, at a concentration of between 5 ppb and 350 ppb.
- the hydrogel has a water content of, for example, between 37.5% and 70% by weight.
- Exemplary hydrogel materials include a tetrapolymer of hydroxymethylmethacrylate, ethylene glycol, dimethylmethacrylate, and methacrylic acid.
- Other examples of hydrogels include those including an ionic or non-ionic polymer and those including etafilcon A, vifilcon A, or polymacon B.
- the growth factor is capable of being passively released into an environment, e.g., an ocular environment, under ambient or existing conditions.
- the hydrogel may be shaped as a contact lens, e.g., one capable of correcting vision.
- a contact lens may be capable of correcting vision in the range of +8.0 to ⁇ 8.0 diopters, including plano, and may have a base curve between 8.0 and 9.0.
- the invention further features a method for making a hydrogel drug delivery system.
- This method includes the steps of providing a hydrogel; washing the hydrogel in an isotonic saline solution; partially desiccating the lens; and placing the washed and partially desiccated hydrogel in an aqueous solution, e.g., having a pH between 6.9 and 7.4, of between 0.01 and 10 ng growth factor, e.g., epidermal growth factor, platelet derived growth factor, hepatocytic growth factor, or combinations thereof, per ⁇ l, wherein growth factor is passively transferred into the hydrogel to produce the hydrogel drug delivery system.
- the concentration of growth factor in the hydrogel after soaking is, for example, between 5 and 350 ppb.
- the hydrogel is placed in the solution of growth factor for at least 30 minutes.
- the invention features a method for treating a wound.
- the method includes the steps of providing a hydrogel containing a growth factor as described above; placing said hydrogel in contact with the wound, wherein the growth factor is passively released from the hydrogel to treat the wound.
- the hydrogel further acts as a protective shield against mechanical abuse.
- the wound is in endothelial tissue, epithelial tissue, the lung, the skin, or the digestive tract.
- the hydrogel may be placed in a body cavity.
- the passively released growth factor causes a reduction in pain compared to a wound not contacted with the polymeric hydrogel.
- ambient conditions room temperature and pressure.
- substantially pure is meant having a purity of greater than 75% by weight.
- a growth factor of the invention is, for example, greater than 85%, 90%, 95%, or even 99% pure.
- Use of the term is intended to define purity from other biological compounds, e.g., proteins, carbohydrates, and lipids that are commonly associated with the growth factor in vivo.
- treating is meant the medical management of a patient with the intent that a prevention, cure, stabilization, or amelioration of the symptoms will result.
- This term includes active treatment, that is, treatment directed specifically toward improvement of the disorder; palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disorder; preventive treatment, that is, treatment directed to prevention of the disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the disorder.
- treatment also includes symptomatic treatment, that is, treatment directed toward constitutional symptoms of the disorder. The term further includes the promotion of wound closure or healing.
- wound is meant an injury to any tissue.
- wounds include burns, lacerations, abrasions, bites, surgical wounds, puncture wounds, and ulcers.
- This invention provides a polymeric drug delivery system including a hydrogel containing a growth factor, e.g., EGF. Allowing passive transference of the growth factor from a dilute aqueous solution into the hydrogel produces the delivery system.
- the hydrogel when placed in contact with a wound, delivers a low concentration of the growth factor over an extended period of time. This sustained delivery accelerates the wound healing process while avoiding potential damaging effects of localized delivery of high concentrations of compounds.
- Hydrogels This invention may employ different polymer compositions that are useful in the treatment of a variety of tissues.
- conventional soft contact lenses can be used and can be either ionic or non-ionic hydrogels containing between 37.5% -70% water by weight and can have any base curve, e.g. from 8.0 to 9.0.
- the contact lenses may also have the ability to correct vision, for example over a range of diopters of +8.0 to ⁇ 8.0, including piano.
- Exemplary hydrogel contact lens materials include etafilcon A, vifilcon A, polymacon B, and a tetrapolymer of hydroxymethylmethacrylate, ethylene glycol, dimethylmethacrylate, and methacrylic acid.
- hydrogels may be insoluble or may dissolve over time in vivo, e.g., over one day or one week.
- the growth factor is passively delivered, for example, by diffusion out of the hydrogel or by release as the hydrogel dissolves.
- the drug delivery system is produced by partially desiccating a hydrated hydrogel (or equivalently partially hydrating a desiccated hydrogel).
- the desiccation step removes, for example, approximately (within ⁇ 2%) 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, or 75% of the water in a hydrogel. Desiccation can occur, for example, by exposure of the hydrogel to ambient or humidity controlled air, by heating the hydrogel for a specific period of time, or by blowing dried gas, such as N 2 , over the hydrogel.
- the hydrogel is saturated with physiological (isotonic) saline prior to desiccation.
- the partially desiccated hydrogel is then soaked, e.g., for at least 30 minutes, in a dilute aqueous solution of growth factor, e.g., at a pH between 6.9 to 7.4.
- the hydrogels may also be soaked for at least 1 hour, 6 hours, 12 hours, or 24 hours.
- the concentration of growth factor into which the hydrogel is placed is typically 10 ng/ ⁇ l or less, e.g., at most 5 ng/ ⁇ l, 1 ng/ ⁇ l, 0.1 ng/ ⁇ l, or 0.01 ng/ ⁇ l. Higher concentrations may also be used, for example, to reduce the soaking time.
- the growth factor is passively transfered into the hydrogel. This transfer occurs at least in part by rehydrating the hydrogel. Diffusion of the growth factor into the water in the hydrogel may also occur.
- the concentration of growth factor transferred to the hydrogel is substantially lower than the solution in which the hydrogel is soaked.
- the concentration of growth factor in the hydrogel is at least 2 ⁇ , 5 ⁇ , or 10 ⁇ less than that of the soaking solution.
- the water content and type of hydrogel, time and conditions, e.g., temperature of soaking, composition of the soaking solution (e.g., ionic strength and pH), and type of growth factor employed also may influence the concentration of growth factor in the drug delivery system.
- the water content of the hydrogel also helps to determine the total amount of growth factor present in a hydrogel.
- the water content of a hydrogel represents another variable by which to control the amount of growth factor delivered to a tissue.
- hydrogel containing a specified amount of growth factor can be accomplished by routine experimentation by one skilled in the art.
- exemplary hydrogels include between 5 and 350 ppb of growth factor, for example, between 5 and 250 ppb, 5 and 100 ppb, 5 and 50 ppb, or 5 and 10 ppb.
- Growth factors are a heterogeneous group of proteins capable of stimulating growth and the multiplication of cells.
- Exemplary growth factors include epidermal growth factor, platelet derived growth factor, hepatocytic growth factor, and combinations thereof. These growth factors may be natural, synthetic, or recombinant growth factors or growth factor derivatives from any animal, for example, humans, or any domesticated animal or pet species. Such growth factors also include biologically active growth factors and analogs.
- Peptide growth factors play important biological roles by regulating many of the processes involved in normal wound healing including migration, mitosis, and differentiation of cells. Growth factors are commercially available or may be isolated using methods known in the art.
- the hydrogels of the invention may also contain medicaments other than growth factors.
- additional compounds include, without limitation, analgesics, anti-inflammatory drugs, antibodies, meganins, self-proteins, pharmaceutical drugs, and antibiotic compounds.
- preservatives are non-ideal as they may transfer to a hydrogel disproportionately and cause cytotoxicity.
- a drug delivery system of the invention may be placed in contact with a damaged tissue.
- the lens may simply be placed in the eye normally in order to deliver the growth factor.
- the hydrogel may be part of a bandage or may be adhered (e.g., by adhesives or sutures) to the wounded tissue. If the hydrogel is placed internally in a patient, the hydrogel is advantageously biodegradable.
- Hydrogels may be considered to be disposable and may be replaced after a specified period of time. Alternatively, a hydrogel that has a depleted amount of growth factor may be recycled by desiccating and soaking the hydrogel again.
- the invention may be used in conjunction with healing many types of wounds, including, without limitation, ocular, oral, lung, digestive tract, skin, large intestine, small intestine, colon, and other wounds to endothelial, mucosal, or epithelial tissues.
- the invention provides accelerated healing by delivering a growth factor to an injured tissue. This delivery occurs by passive transfer and allows medications to be released into fluids of the body, e.g., ocular fluid.
- the growth factor stimulates proliferation of cells surrounding a wound to close the wound and replace damaged cells.
- the hydrogel which provides a timed release of the growth factor, a lesser amount of growth factor may in many cases be needed to effect wound healing than if, e.g., topical solutions, such as eye drops are used. Accelerated healing may also reduce the pain and inflammation associated with a particular wound and may help prevent infection.
- the hydrogel may also act as a physical barrier to provide protection from mechanical abuse and to prevent adherence of the healing tissue to adjacent tissues.
- the wound is an ocular wound, e.g., in epithelial, endothelial, or retinal tissue.
- the invention is of particular utility after vision correcting surgery, such as LASIK, PRK, or LASEK.
- Soft and collagen contact lenses may be utilized to minimize post-surgical epithelial trauma and provide a stable healing environment.
- PRK typically requires a therapeutic contact lens for 3-4 days, and post-operative therapeutic drops are often prescribed.
- the hydrogel may be shaped as a contact lens that acts as a reservoir for the growth factor and can serve to protect the leading edge of wound healing from normal mechanical abuse.
- the growth factor gradually delivered in a low concentration from the lens obviates the need for therapeutic drops.
- Therapeutic drops often include high concentrations of drugs because the majority of the drop is excreted from the eye in a short period of time. These high concentrations can cause additional damage to a wound, which is avoided by the use of the present, localized time-release drug delivery system.
- An exemplary drug delivery system was prepared as follows. Contact lenses were removed from their package and rinsed with saline to remove contact lens packing solution. The hydrogel lens materials were allowed to desiccate for 10-30 seconds. The hydrogel lens materials were placed into physiological saline that contained epidermal growth factor (EGF) at concentrations of 10 ng/ ⁇ l or 5.0 ng/ ⁇ l for at least 30 minutes. Lower concentrations may also be used. Longer passive transference times may also be used. Untreated or control lenses were placed in physiological saline without EGF.
- EGF epidermal growth factor
- Epithelial Cells and Tissue Epithelial (rabbit corneal epithelial cells) cells were seeded on a dish and contacted with control and EGF-containing contact lenses. At 48 hours there was a 25% difference in the closure rate between the EGF-treated cells and the non-EGF treated cells. At 72 hours, there was a 43% difference in the closure rate between the EGF-treated epithelial tissue and the controls.
- the hydrogel material that was used was vifilcon A, an ionic polymer with a water content of 55%. The polymer had been incubated with 10 ng/ ⁇ l for one hour at 4° C. prior to use in the experiments. The lens contained approximately 1 ng/ ⁇ l of EGF.
- Closure rates were calculated by direct measurement of the diameter of the wound. Measurements were taken daily.
- a vifilcon A lens was incubated under the same conditions as above with 5.0 ng/ ⁇ l of EGF and then contacted with an epithelial “wound” as above.
- the lens contained approximately 0.5 ng/ ⁇ l of EGF.
- closure rate between controls and EGF treated hydrogel materials.
- closure rate there was also a 21% difference in the closure rate.
- the rate of wound healing increased with increased exposure of the hydrogel material to the wound. Further, compared to a wound not contacted with any lens, at 48 hours there was a 31% difference in the healing rates.
- Healing for tissue exposed to a lens soaked in 10 ng/ ⁇ l of EGF increased from 14% at 48 hours to 25% at 72 hours.
- Endothelial Cells and Tissue Wounds caused in endothelial tissue (bovine corneal endothelial cells) were also healed by release of EGF from a vifilcon A lens.
- the lens soaked in 10 ng/ ⁇ l of EGF as above, showed a 73% difference in healing rates at 48 hours compared to a control. At 72 hours, the EGF-treated tissue had completely healed. In the control group, less than half (43%) of the tissue had healed.
- the same lens material exposed to 5 ng/ ⁇ l of EGF showed a 31% difference in closure rate at 48 hours between the EGF treated group and the controls. At 72 hours, 53% of the tissue had healed in the EGF treated group, compared to 43% in the control.
- the concentration of EGF used in the soaking solution was 10 ng/ ⁇ l.
- the EGF treated tissue showed a 54% increase in the healing rate (wound closure rate) as compared to controls.
- the lenses were prepared using a soaking solution of 10 ng/ ⁇ l of EGF.
- the wound was 60% closed in the treated group and 27% closed in the non-treated group.
- the difference in closure between the treated and untreated groups was 62%.
- the wound had closed by 80%, while in the untreated group, the wound had closed by 46.8%.
Abstract
Description
- In general, the invention relates to the fields of hydrogels, drug delivery systems, and wound healing.
- Corneal wounds caused by injury, disease, or surgery represent a serious medical condition that may lead to loss of sight. For example, persistent epithelial defects can lead to stromal melting, which causes serious visual dysfunction. Wound healing of corneal mucosal tissue has taken on increased importance with the advent of laser corrective surgery to re-establish normal vision for people who do not wish to wear contact lenses or spectacles. These laser surgical methods are used to correct vision for nearsightedness (myopia), farsightedness (hyperopia), and astigmatism. The methods include laser in situ keratomileusis (LASIK), laser epithelial keratomileusis (LASEK), and photo-refractive keratectomy (PRK).
- LASIK refers to the use of a laser to reshape the cornea without invading the adjacent cell layers. During the LASIK procedure, a microkeratome is used to separate the surface layers of the cornea and create a corneal flap (160-180 microns deep). This flap stays attached to the rest of the cornea and is folded back on one side to expose the stroma of the cornea. The laser delivers pulses of ultraviolet light onto the inner cornea (stroma). Each pulse removes a microscopic layer of the inner cornea to reshape the surface of the cornea. For nearsighted patients, the procedure flattens the cornea. For farsighted patients, the procedure increases the curvature of the cornea. For astigmatism, selected tissues are removed at certain angles to make the cornea more spherical in shape. After exposure to the laser is completed, the corneal flap is replaced where it bonds without the need for stitches. The anterior layers of the cornea (epithelium, Bowman's Layer) are largely preserved. Once the surgery is completed, the eye is left to heal normally with the exception of eye drops, which are used to prevent infection & swelling, with varying degrees of success. Following the surgery, patients are able to see clearly without depending on glasses or contacts.
- During PRK, the surgeon removes the epithelium (the anterior layer of the cornea or Bowman's Layer), which is a thin layer of protective skin that covers the cornea. This layer can be removed with an excimer laser or a brush. During the procedure, the patient stares at a fixation light. In less than a minute, the laser removes the proper amount of tissue while it reshapes the surface of the cornea. The excimer laser delivers pulses of ultraviolet light into the cornea. This exposure to laser radiation reduces or eliminates nearsightedness by flattening the central cornea and relocating the focal point of the lens onto the retina rather than in front of it, which produces sharper vision. Following surgery, a bandage contact lens is placed on the eye for 2-3 days. Because the epithelium was removed, patients may experience blurry vision for three to five days. Eye drops and the contact lens are effective in reducing postoperative discomfort. The purpose of the contact lens given to PRK patients post-surgically is to protect the leading edge of the corneal epithelium that is regenerating along the surface of the eye, post-surgery. As patients blink, the newer leading edge of the epithelium may be removed. As a result, recovery takes longer and there is an increased risk of infection.
- LASEK is similar to PRK but the epithelium is detached by using an alcohol solution that weakens the epithelium and allows it to fold back into a flap. A laser is then used to re-shape the cornea and correct vision acuity.
- All three procedures can result in corneal epithelial defects, and inflammation and infection may also occur. These complications can lead to acuity regression or other adverse effects. Wound healing is thus of critical importance for the outcome of surgery. There exists a need, therefore, for devices that promote healing of corneal wounds.
- The present invention features hydrogel drug delivery systems and methods of producing and using such systems for the treatment of wounds. The systems are based on a hydrogel into which a growth factor, e.g., epidermal growth factor (EGF), is passively transferred from a dilute aqueous solution. When placed in contact with a wounded tissue, the growth factor passively transfers out of the hydrogel to provide accelerated healing and a concomitant reduction in pain. The amount of growth factor absorbed into the hydrogel is low, e.g., ≦350 ppb, but this amount surprisingly is effective in producing a therapeutic effect likely because the delivery system is localized and provides a sustained release of the factor. The systems are applicable to ocular wounds, especially after vision correcting surgery, as well as other wound treatments.
- Accordingly, in one aspect, the invention features a polymeric hydrogel that comprises a substantially pure growth factor, e.g., epidermal growth factor, platelet derived growth factor, hepatocytic growth factor, or combinations thereof, at a concentration of between 5 ppb and 350 ppb. The hydrogel has a water content of, for example, between 37.5% and 70% by weight. Exemplary hydrogel materials include a tetrapolymer of hydroxymethylmethacrylate, ethylene glycol, dimethylmethacrylate, and methacrylic acid. Other examples of hydrogels include those including an ionic or non-ionic polymer and those including etafilcon A, vifilcon A, or polymacon B. In various embodiments, the growth factor is capable of being passively released into an environment, e.g., an ocular environment, under ambient or existing conditions. In other embodiments, the hydrogel may be shaped as a contact lens, e.g., one capable of correcting vision. Such a contact lens may be capable of correcting vision in the range of +8.0 to −8.0 diopters, including plano, and may have a base curve between 8.0 and 9.0.
- The invention further features a method for making a hydrogel drug delivery system. This method includes the steps of providing a hydrogel; washing the hydrogel in an isotonic saline solution; partially desiccating the lens; and placing the washed and partially desiccated hydrogel in an aqueous solution, e.g., having a pH between 6.9 and 7.4, of between 0.01 and 10 ng growth factor, e.g., epidermal growth factor, platelet derived growth factor, hepatocytic growth factor, or combinations thereof, per μl, wherein growth factor is passively transferred into the hydrogel to produce the hydrogel drug delivery system. The concentration of growth factor in the hydrogel after soaking is, for example, between 5 and 350 ppb. In one embodiment, the hydrogel is placed in the solution of growth factor for at least 30 minutes.
- In another aspect, the invention features a method for treating a wound. The method includes the steps of providing a hydrogel containing a growth factor as described above; placing said hydrogel in contact with the wound, wherein the growth factor is passively released from the hydrogel to treat the wound. In one embodiment, the hydrogel further acts as a protective shield against mechanical abuse. In various embodiments, the wound is in endothelial tissue, epithelial tissue, the lung, the skin, or the digestive tract. The hydrogel may be placed in a body cavity. In another embodiment, the passively released growth factor causes a reduction in pain compared to a wound not contacted with the polymeric hydrogel.
- By “ambient conditions” is meant room temperature and pressure.
- By “existing conditions” is meant in situ, as in the eye or other body system.
- By “substantially pure” is meant having a purity of greater than 75% by weight. A growth factor of the invention is, for example, greater than 85%, 90%, 95%, or even 99% pure. Use of the term is intended to define purity from other biological compounds, e.g., proteins, carbohydrates, and lipids that are commonly associated with the growth factor in vivo.
- By “treating” is meant the medical management of a patient with the intent that a prevention, cure, stabilization, or amelioration of the symptoms will result. This term includes active treatment, that is, treatment directed specifically toward improvement of the disorder; palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disorder; preventive treatment, that is, treatment directed to prevention of the disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the disorder. The term “treatment” also includes symptomatic treatment, that is, treatment directed toward constitutional symptoms of the disorder. The term further includes the promotion of wound closure or healing.
- By “wound” is meant an injury to any tissue. Examples of wounds include burns, lacerations, abrasions, bites, surgical wounds, puncture wounds, and ulcers.
- All percentages described in the present invention are by weight unless otherwise specified.
- This invention provides a polymeric drug delivery system including a hydrogel containing a growth factor, e.g., EGF. Allowing passive transference of the growth factor from a dilute aqueous solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with a wound, delivers a low concentration of the growth factor over an extended period of time. This sustained delivery accelerates the wound healing process while avoiding potential damaging effects of localized delivery of high concentrations of compounds.
- Drug Delivery System
- Hydrogels. This invention may employ different polymer compositions that are useful in the treatment of a variety of tissues. For example, in the ocular environment, conventional soft contact lenses can be used and can be either ionic or non-ionic hydrogels containing between 37.5% -70% water by weight and can have any base curve, e.g. from 8.0 to 9.0. The contact lenses may also have the ability to correct vision, for example over a range of diopters of +8.0 to −8.0, including piano. Exemplary hydrogel contact lens materials include etafilcon A, vifilcon A, polymacon B, and a tetrapolymer of hydroxymethylmethacrylate, ethylene glycol, dimethylmethacrylate, and methacrylic acid. These materials may also be employed, in other physical forms, in treating wounds in other tissues. Other suitable hydrogel materials are known to those skilled in the art. The hydrogels may be insoluble or may dissolve over time in vivo, e.g., over one day or one week. The growth factor is passively delivered, for example, by diffusion out of the hydrogel or by release as the hydrogel dissolves.
- The drug delivery system is produced by partially desiccating a hydrated hydrogel (or equivalently partially hydrating a desiccated hydrogel). The desiccation step removes, for example, approximately (within ±2%) 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, or 75% of the water in a hydrogel. Desiccation can occur, for example, by exposure of the hydrogel to ambient or humidity controlled air, by heating the hydrogel for a specific period of time, or by blowing dried gas, such as N2, over the hydrogel. In one embodiment, the hydrogel is saturated with physiological (isotonic) saline prior to desiccation. The partially desiccated hydrogel is then soaked, e.g., for at least 30 minutes, in a dilute aqueous solution of growth factor, e.g., at a pH between 6.9 to 7.4. The hydrogels may also be soaked for at least 1 hour, 6 hours, 12 hours, or 24 hours. The concentration of growth factor into which the hydrogel is placed is typically 10 ng/μl or less, e.g., at most 5 ng/μl, 1 ng/μl, 0.1 ng/μl, or 0.01 ng/μl. Higher concentrations may also be used, for example, to reduce the soaking time. The growth factor is passively transfered into the hydrogel. This transfer occurs at least in part by rehydrating the hydrogel. Diffusion of the growth factor into the water in the hydrogel may also occur.
- Typically, the concentration of growth factor transferred to the hydrogel is substantially lower than the solution in which the hydrogel is soaked. For example, the concentration of growth factor in the hydrogel is at least 2×, 5×, or 10× less than that of the soaking solution. The water content and type of hydrogel, time and conditions, e.g., temperature of soaking, composition of the soaking solution (e.g., ionic strength and pH), and type of growth factor employed also may influence the concentration of growth factor in the drug delivery system. The water content of the hydrogel also helps to determine the total amount of growth factor present in a hydrogel. Thus, the water content of a hydrogel represents another variable by which to control the amount of growth factor delivered to a tissue. The production of a hydrogel containing a specified amount of growth factor can be accomplished by routine experimentation by one skilled in the art. Exemplary hydrogels include between 5 and 350 ppb of growth factor, for example, between 5 and 250 ppb, 5 and 100 ppb, 5 and 50 ppb, or 5 and 10 ppb.
- Growth factors. Growth factors are a heterogeneous group of proteins capable of stimulating growth and the multiplication of cells. Exemplary growth factors include epidermal growth factor, platelet derived growth factor, hepatocytic growth factor, and combinations thereof. These growth factors may be natural, synthetic, or recombinant growth factors or growth factor derivatives from any animal, for example, humans, or any domesticated animal or pet species. Such growth factors also include biologically active growth factors and analogs. Peptide growth factors play important biological roles by regulating many of the processes involved in normal wound healing including migration, mitosis, and differentiation of cells. Growth factors are commercially available or may be isolated using methods known in the art.
- Other compounds. The hydrogels of the invention may also contain medicaments other than growth factors. These additional compounds include, without limitation, analgesics, anti-inflammatory drugs, antibodies, meganins, self-proteins, pharmaceutical drugs, and antibiotic compounds.
- The use of preservatives is non-ideal as they may transfer to a hydrogel disproportionately and cause cytotoxicity.
- Treatment. To treat a wound, a drug delivery system of the invention may be placed in contact with a damaged tissue. When the system is shaped as a contact lens, the lens may simply be placed in the eye normally in order to deliver the growth factor. In order to effect accelerated healing of other wounds, the hydrogel may be part of a bandage or may be adhered (e.g., by adhesives or sutures) to the wounded tissue. If the hydrogel is placed internally in a patient, the hydrogel is advantageously biodegradable.
- Hydrogels may be considered to be disposable and may be replaced after a specified period of time. Alternatively, a hydrogel that has a depleted amount of growth factor may be recycled by desiccating and soaking the hydrogel again.
- Treatment Approaches
- The invention may be used in conjunction with healing many types of wounds, including, without limitation, ocular, oral, lung, digestive tract, skin, large intestine, small intestine, colon, and other wounds to endothelial, mucosal, or epithelial tissues. As stated above, the invention provides accelerated healing by delivering a growth factor to an injured tissue. This delivery occurs by passive transfer and allows medications to be released into fluids of the body, e.g., ocular fluid. The growth factor stimulates proliferation of cells surrounding a wound to close the wound and replace damaged cells. Because the growth factor is localized by the hydrogel, which provides a timed release of the growth factor, a lesser amount of growth factor may in many cases be needed to effect wound healing than if, e.g., topical solutions, such as eye drops are used. Accelerated healing may also reduce the pain and inflammation associated with a particular wound and may help prevent infection. In addition, the hydrogel may also act as a physical barrier to provide protection from mechanical abuse and to prevent adherence of the healing tissue to adjacent tissues.
- Ocular Wounds. In one embodiment, the wound is an ocular wound, e.g., in epithelial, endothelial, or retinal tissue. The invention is of particular utility after vision correcting surgery, such as LASIK, PRK, or LASEK. Soft and collagen contact lenses may be utilized to minimize post-surgical epithelial trauma and provide a stable healing environment. PRK typically requires a therapeutic contact lens for 3-4 days, and post-operative therapeutic drops are often prescribed. In the present invention, the hydrogel may be shaped as a contact lens that acts as a reservoir for the growth factor and can serve to protect the leading edge of wound healing from normal mechanical abuse. The growth factor gradually delivered in a low concentration from the lens obviates the need for therapeutic drops. Therapeutic drops often include high concentrations of drugs because the majority of the drop is excreted from the eye in a short period of time. These high concentrations can cause additional damage to a wound, which is avoided by the use of the present, localized time-release drug delivery system.
- A further understanding of the invention may be obtained from the following non-limiting examples.
- Production of a Drug Delivery System.
- An exemplary drug delivery system was prepared as follows. Contact lenses were removed from their package and rinsed with saline to remove contact lens packing solution. The hydrogel lens materials were allowed to desiccate for 10-30 seconds. The hydrogel lens materials were placed into physiological saline that contained epidermal growth factor (EGF) at concentrations of 10 ng/μl or 5.0 ng/μl for at least 30 minutes. Lower concentrations may also be used. Longer passive transference times may also be used. Untreated or control lenses were placed in physiological saline without EGF.
- Healing of Ocular Tissue.
- Ocular cells were placed into a sterile plastic dish. This dish contained a 5-mm disk. The purpose of the disk was to prevent cells from growing in the covered area. When the disk was removed, a 5-mm “wound” or “hole” was present.
- Contact lenses were then added to these cell sheets with the wounds. The lenses were left in contact with the cell sheets for a minimum of 30 minutes. Minimal medium was used to maintain the cell cultures. Cells were incubated at 35° C.±2° C. in 5% CO2. Contact lenses with or without EGF were produced as in Example 1. The contact lenses used were polymacon B, vifilcon A, and lidofilcon A hydrogel polymers.
- The cell sheets were then viewed over time, and the diameter of the hole was measured.
- The results are expressed in terms of closure of the in vitro wound over time.
- Epithelial Cells and Tissue. Epithelial (rabbit corneal epithelial cells) cells were seeded on a dish and contacted with control and EGF-containing contact lenses. At 48 hours there was a 25% difference in the closure rate between the EGF-treated cells and the non-EGF treated cells. At 72 hours, there was a 43% difference in the closure rate between the EGF-treated epithelial tissue and the controls. The hydrogel material that was used was vifilcon A, an ionic polymer with a water content of 55%. The polymer had been incubated with 10 ng/μl for one hour at 4° C. prior to use in the experiments. The lens contained approximately 1 ng/μl of EGF.
- Closure rates were calculated by direct measurement of the diameter of the wound. Measurements were taken daily.
- In a related series of experiments, a vifilcon A lens was incubated under the same conditions as above with 5.0 ng/μl of EGF and then contacted with an epithelial “wound” as above. The lens contained approximately 0.5 ng/μl of EGF. At 48 hours, there was a 21% closure rate difference between controls and EGF treated hydrogel materials. At 72 hours, there was also a 21% difference in the closure rate. These results indicated that over a 72-hour period, the relative healing rates remained essentially the same for the treated and non-treated epithelial tissue, with the epithelial tissue treated with EGF always having an accelerated rate of healing.
- The rate of wound healing increased with increased exposure of the hydrogel material to the wound. Further, compared to a wound not contacted with any lens, at 48 hours there was a 31% difference in the healing rates. Healing for tissue exposed to a lens soaked in 10 ng/μl of EGF increased from 14% at 48 hours to 25% at 72 hours.
- Endothelial Cells and Tissue. Wounds caused in endothelial tissue (bovine corneal endothelial cells) were also healed by release of EGF from a vifilcon A lens. The lens, soaked in 10 ng/μl of EGF as above, showed a 73% difference in healing rates at 48 hours compared to a control. At 72 hours, the EGF-treated tissue had completely healed. In the control group, less than half (43%) of the tissue had healed. The same lens material exposed to 5 ng/μl of EGF showed a 31% difference in closure rate at 48 hours between the EGF treated group and the controls. At 72 hours, 53% of the tissue had healed in the EGF treated group, compared to 43% in the control.
- Lidofilcon A hydrogel (non-ionic, water content=70%) materials were evaluated for their ability to deliver EGF to endothelial tissue to close wounds. The concentration of EGF used in the soaking solution was 10 ng/μl. At 48 hours, the EGF treated tissue showed a 54% increase in the healing rate (wound closure rate) as compared to controls. At 72 hours, there was a difference of 44%.
- A third material, Polymacon B, that is non-ionic and has a water content of 38%, was also evaluated for the ability to deliver EGF to wounds. The lenses were prepared using a soaking solution of 10 ng/μl of EGF. At 48 hours, the wound was 60% closed in the treated group and 27% closed in the non-treated group. At 72 hours, the difference in closure between the treated and untreated groups was 62%. In the EGF treated group at 72 hours, the wound had closed by 80%, while in the untreated group, the wound had closed by 46.8%.
- Other Embodiments
- Modifications and variations of the described methods of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific desirable embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention, which are obvious to those skilled in the art, are intended to be within the scope of the invention.
- All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually to be incorporated by reference.
- Other embodiments are within the claims.
Claims (33)
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/132,843 US20030203032A1 (en) | 2002-04-25 | 2002-04-25 | Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
US10/340,434 US7169406B2 (en) | 2002-04-25 | 2003-01-10 | Growth factor delivery systems for the healing of wounds and the prevention of inflammation and disease |
PCT/US2003/012257 WO2003090662A2 (en) | 2002-04-25 | 2003-04-22 | Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
CA002483265A CA2483265A1 (en) | 2002-04-25 | 2003-04-22 | Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
JP2003587301A JP2005529122A (en) | 2002-04-25 | 2003-04-22 | Growth factor delivery system for wound healing and methods of preventing inflammation and disease |
EP03719865A EP1503730A4 (en) | 2002-04-25 | 2003-04-22 | Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
IL16482203A IL164822A0 (en) | 2002-04-25 | 2003-04-22 | Growth factor delivery system for the healing of wounds and the prevention and disease |
AU2003222668A AU2003222668A1 (en) | 2002-04-25 | 2003-04-22 | Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
US10/971,820 US20050085758A1 (en) | 2002-04-25 | 2004-10-22 | Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
ZA200408660A ZA200408660B (en) | 2002-04-25 | 2004-10-26 | Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
US11/096,736 US7618643B2 (en) | 2002-04-25 | 2005-04-01 | Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/132,843 US20030203032A1 (en) | 2002-04-25 | 2002-04-25 | Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/340,434 Continuation-In-Part US7169406B2 (en) | 2002-04-25 | 2003-01-10 | Growth factor delivery systems for the healing of wounds and the prevention of inflammation and disease |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030203032A1 true US20030203032A1 (en) | 2003-10-30 |
Family
ID=29248849
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/132,843 Abandoned US20030203032A1 (en) | 2002-04-25 | 2002-04-25 | Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
US10/340,434 Expired - Lifetime US7169406B2 (en) | 2002-04-25 | 2003-01-10 | Growth factor delivery systems for the healing of wounds and the prevention of inflammation and disease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/340,434 Expired - Lifetime US7169406B2 (en) | 2002-04-25 | 2003-01-10 | Growth factor delivery systems for the healing of wounds and the prevention of inflammation and disease |
Country Status (2)
Country | Link |
---|---|
US (2) | US20030203032A1 (en) |
ZA (1) | ZA200408660B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050208102A1 (en) * | 2003-04-09 | 2005-09-22 | Schultz Clyde L | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
US20080107713A1 (en) * | 2006-11-08 | 2008-05-08 | Orilla Werhner C | Contact lens as a sustained drug delivery implant |
US20080317819A1 (en) * | 2007-06-21 | 2008-12-25 | Orilla Werhner C | Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas |
US20080318843A1 (en) * | 2003-04-09 | 2008-12-25 | Directcontact Llc | Device and Method for the Delivery of Drugs for the Treatment of Posterior Segment Disease |
US20100239637A1 (en) * | 2008-12-11 | 2010-09-23 | Massachusetts Institute Of Technology | Contact lens drug delivery device |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ526157A (en) * | 2003-05-27 | 2006-01-27 | Velvet Antler Res New Zealand | Method for the extraction of deer antler and use of the extract therefrom |
US20050275799A1 (en) * | 2004-03-10 | 2005-12-15 | Marmo J C | Contact lenses, package systems, and method for promoting a healthy epithelium of an eye |
CN1939534B (en) * | 2005-09-27 | 2010-12-01 | 长春金赛药业股份有限公司 | Externally-applied preparation containing human growth incretion or human granular leukocyte macrophage stimulus factor for treating injury ulceration |
WO2008005276A2 (en) * | 2006-06-30 | 2008-01-10 | Directcontact Llc | Growth factor delivery system containing antimicrobial agents |
CA2664790C (en) | 2006-09-29 | 2015-11-24 | Johnson & Johnson Vision Care, Inc. | Methods and ophthalmic devices used in the treatment of ocular allergies |
US9248159B2 (en) | 2008-10-14 | 2016-02-02 | Robert Stanley Berman | MRSA bactericidal topical gel |
US20100106128A1 (en) * | 2008-10-23 | 2010-04-29 | Shane Mao | Contact lens cases for delivery of ophthalmic agents |
TW201302244A (en) | 2011-07-08 | 2013-01-16 | Univ Nat Chiao Tung | Drug-carrying contact lens and manufacturing method thereof |
AR089518A1 (en) * | 2012-12-27 | 2014-08-27 | Vega Villavicencio Parsival | SEMIPERMEABLE PORTABLE ARTIFICIAL COSTRA |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4931279A (en) * | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
US5433745A (en) * | 1993-10-13 | 1995-07-18 | Allergan, Inc. | Corneal implants and methods for producing same |
US5472703A (en) * | 1993-03-02 | 1995-12-05 | Johnson & Johnson Vision Products, Inc. | Ophthalmic lens with anti-toxin agent |
US5597381A (en) * | 1993-06-03 | 1997-01-28 | Massachusetts Eye And Ear Infirmary | Methods for epi-retinal implantation |
US5607688A (en) * | 1989-09-26 | 1997-03-04 | Cejkova; Jitka | Contact lens of hydrophilic gels with inhibitor and swelling agent |
US5695509A (en) * | 1995-03-10 | 1997-12-09 | El Hage; Sami G. | Aspherical optical molds for continuous reshaping the cornea based on topographical analysis |
US5723131A (en) * | 1995-12-28 | 1998-03-03 | Johnson & Johnson Vision Products, Inc. | Contact lens containing a leachable absorbed material |
US5973089A (en) * | 1995-04-04 | 1999-10-26 | Novartis Ag | Polymerizable perfluoroalkylether macromer |
US6124273A (en) * | 1995-06-09 | 2000-09-26 | Chitogenics, Inc. | Chitin hydrogels, methods of their production and use |
US6143315A (en) * | 1997-07-24 | 2000-11-07 | Wang; Ming X. | Biochemical contact lens for treating injured corneal tissue |
US6261545B1 (en) * | 1996-09-13 | 2001-07-17 | Advanced Medicine Research Institute | Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders |
US6410045B1 (en) * | 1999-02-22 | 2002-06-25 | Clyde Lewis Schultz | Drug delivery system for antiglaucomatous medication |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4617299A (en) * | 1983-12-19 | 1986-10-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
US4668506A (en) * | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
US4731244A (en) * | 1985-11-13 | 1988-03-15 | Ortho Pharmaceutical Corporation | Monoclonal antibody therapy |
US4983580A (en) * | 1986-04-04 | 1991-01-08 | Allergan, Inc. | Methods and materials for use in corneal wound healing |
US4981841A (en) * | 1986-04-04 | 1991-01-01 | Allergan, Inc. | Methods and materials for use in corneal wound healing |
US5171318A (en) * | 1987-11-09 | 1992-12-15 | Chiron Ophthalmics, Inc. | Treated corneal prosthetic device |
US5053388A (en) * | 1987-11-09 | 1991-10-01 | Chiron Ophthalmics, Inc. | Wound healing composition and method |
US5156622A (en) * | 1988-03-02 | 1992-10-20 | Thompson Keith P | Apparatus and process for application and adjustable reprofiling of synthetic lenticules for vision correction |
US4923467A (en) * | 1988-03-02 | 1990-05-08 | Thompson Keith P | Apparatus and process for application and adjustable reprofiling of synthetic lenticules for vision correction |
US5104408A (en) * | 1988-03-02 | 1992-04-14 | Thompson Keith P | Apparatus and process for application and adjustable reprofiling of synthetic lenticules for vision correction |
US4973466A (en) * | 1988-06-21 | 1990-11-27 | Chiron Ophthalmics, Inc. | Wound-healing dressings and methods |
US5124155A (en) * | 1988-06-21 | 1992-06-23 | Chiron Ophthalmics, Inc. | Fibronectin wound-healing dressings |
US5360611A (en) * | 1988-10-03 | 1994-11-01 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation |
US4939135A (en) * | 1988-10-03 | 1990-07-03 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation |
US5271939A (en) * | 1988-10-03 | 1993-12-21 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation |
US5124392A (en) * | 1988-10-03 | 1992-06-23 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation |
US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
US5565519A (en) * | 1988-11-21 | 1996-10-15 | Collagen Corporation | Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications |
US5196027A (en) * | 1990-05-02 | 1993-03-23 | Thompson Keith P | Apparatus and process for application and adjustable reprofiling of synthetic lenticules for vision correction |
US5212168A (en) * | 1991-02-26 | 1993-05-18 | New England Medical Center Hospital, Inc. | Method of and solution for treating glaucoma |
US5767079A (en) * | 1992-07-08 | 1998-06-16 | Celtrix Pharmaceuticals, Inc. | Method of treating ophthalmic disorders using TGF -β |
US5358706A (en) * | 1992-09-30 | 1994-10-25 | Union Carbide Chemicals & Plastics Technology Corporation | Muco-adhesive polymers |
US5836313A (en) * | 1993-02-08 | 1998-11-17 | Massachusetts Institute Of Technology | Methods for making composite hydrogels for corneal prostheses |
EP0802983B1 (en) * | 1993-06-01 | 2003-05-02 | Chiron Corporation | Expression of urokinase plasminogen activator inhibitors |
US6248715B1 (en) * | 1993-06-01 | 2001-06-19 | Chiron Corporation | Method of treating a urokinase-type plasminogen activator-mediated disorder |
US6063116A (en) * | 1994-10-26 | 2000-05-16 | Medarex, Inc. | Modulation of cell proliferation and wound healing |
US5616502A (en) * | 1995-05-19 | 1997-04-01 | Molecular Probes, Inc. | Non-specific protein staining using merocyanine dyes |
EP0842209B1 (en) * | 1995-07-28 | 2006-10-11 | Genzyme Corporation | Multiblock biodegradable hydrogels for use as controlled release agents for drugs and tissue treatment agents |
US6201164B1 (en) * | 1996-07-11 | 2001-03-13 | Coloplast A/S | Hydrocolloid wound gel |
JPH10158188A (en) * | 1996-11-29 | 1998-06-16 | Senju Pharmaceut Co Ltd | Composition for treating cornea |
US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
US5932205A (en) * | 1997-07-24 | 1999-08-03 | Wang; Ming X. | Biochemical contact lens for treating photoablated corneal tissue |
US6605294B2 (en) | 1998-08-14 | 2003-08-12 | Incept Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
JP2002524425A (en) * | 1998-09-04 | 2002-08-06 | サイオス インコーポレイテッド | Hydrogel compositions for sustained release administration of growth factors |
-
2002
- 2002-04-25 US US10/132,843 patent/US20030203032A1/en not_active Abandoned
-
2003
- 2003-01-10 US US10/340,434 patent/US7169406B2/en not_active Expired - Lifetime
-
2004
- 2004-10-26 ZA ZA200408660A patent/ZA200408660B/en unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4931279A (en) * | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
US5607688A (en) * | 1989-09-26 | 1997-03-04 | Cejkova; Jitka | Contact lens of hydrophilic gels with inhibitor and swelling agent |
US5472703A (en) * | 1993-03-02 | 1995-12-05 | Johnson & Johnson Vision Products, Inc. | Ophthalmic lens with anti-toxin agent |
US5597381A (en) * | 1993-06-03 | 1997-01-28 | Massachusetts Eye And Ear Infirmary | Methods for epi-retinal implantation |
US5433745A (en) * | 1993-10-13 | 1995-07-18 | Allergan, Inc. | Corneal implants and methods for producing same |
US5695509A (en) * | 1995-03-10 | 1997-12-09 | El Hage; Sami G. | Aspherical optical molds for continuous reshaping the cornea based on topographical analysis |
US5973089A (en) * | 1995-04-04 | 1999-10-26 | Novartis Ag | Polymerizable perfluoroalkylether macromer |
US6124273A (en) * | 1995-06-09 | 2000-09-26 | Chitogenics, Inc. | Chitin hydrogels, methods of their production and use |
US5723131A (en) * | 1995-12-28 | 1998-03-03 | Johnson & Johnson Vision Products, Inc. | Contact lens containing a leachable absorbed material |
US6261545B1 (en) * | 1996-09-13 | 2001-07-17 | Advanced Medicine Research Institute | Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders |
US6143315A (en) * | 1997-07-24 | 2000-11-07 | Wang; Ming X. | Biochemical contact lens for treating injured corneal tissue |
US6410045B1 (en) * | 1999-02-22 | 2002-06-25 | Clyde Lewis Schultz | Drug delivery system for antiglaucomatous medication |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050208102A1 (en) * | 2003-04-09 | 2005-09-22 | Schultz Clyde L | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
US20080318843A1 (en) * | 2003-04-09 | 2008-12-25 | Directcontact Llc | Device and Method for the Delivery of Drugs for the Treatment of Posterior Segment Disease |
US9216106B2 (en) | 2003-04-09 | 2015-12-22 | Directcontact Llc | Device and method for the delivery of drugs for the treatment of posterior segment disease |
US20080107713A1 (en) * | 2006-11-08 | 2008-05-08 | Orilla Werhner C | Contact lens as a sustained drug delivery implant |
US20080317819A1 (en) * | 2007-06-21 | 2008-12-25 | Orilla Werhner C | Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas |
US20100239637A1 (en) * | 2008-12-11 | 2010-09-23 | Massachusetts Institute Of Technology | Contact lens drug delivery device |
US8414912B2 (en) | 2008-12-11 | 2013-04-09 | Massachusetts Institute Of Technology | Contact lens drug delivery device |
Also Published As
Publication number | Publication date |
---|---|
US7169406B2 (en) | 2007-01-30 |
US20030203001A1 (en) | 2003-10-30 |
ZA200408660B (en) | 2006-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7618643B2 (en) | Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease | |
Antonio Marinho et al. | LASIK for high myopia: one year experience | |
Taneri et al. | Surface ablation techniques | |
US20030203032A1 (en) | Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease | |
AU694628B2 (en) | Bio-erodible ophthalmic shield | |
Suarez et al. | LASIK for correction of hyperopia and hyperopia with astigmatism | |
Marmer | Therapeutic and protective properties of the corneal collagen shield | |
US9295753B1 (en) | Amniotic membrane preparation and device for use as a lens or as a dressing for promoting healing | |
Kim et al. | Excimer laser photorefractive keratectomy for myopia: two-year follow-up | |
El-Agha et al. | Comparison of photorefractive keratectomy and laser in situ keratomileusis for the treatment of compound hyperopic astigmatism | |
Lavery | Photorefractive keratectomy in 472 eyes | |
RU2309749C1 (en) | Method for treating optic nerve atrophy cases | |
AQUAVELLA | Therapeutic uses of hydrophilic lenses | |
RU2071303C1 (en) | Method to treat turbidity of clear ocular media | |
BG4668U1 (en) | THERAPEUTIC CONTACT LENS WITH BIO MEMBRANE | |
Kumar et al. | Ophthalmic Inserts | |
RU2090165C1 (en) | Method for treatment of cornea injuries | |
Kim et al. | Base curves of therapeutic lenses and their effects on post epi-LASIK vision and pain: a prospective randomized clinical trial | |
RU2090166C1 (en) | Method for treating descementocele | |
RU2164115C2 (en) | Method of treating endophthalmites | |
US20200215121A1 (en) | Amniotic or placental device for ophthalmic use as a dressing with clear center | |
Alkan et al. | Inferonasal XEN gel stent implantation in a refractory glaucoma patient with failed multiple glaucoma filtration surgeries: Case report | |
RU2402303C1 (en) | Method of treating epithelial ingrowth | |
Lee | June consultation# 4 | |
RU2314793C2 (en) | Method for producing ophthalmic films |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: RAPID HEAL INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCHULTZ, CLYDE L.;REEL/FRAME:012840/0431 Effective date: 20020425 |
|
AS | Assignment |
Owner name: RAPIDHEAL LLC, MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 012840 FRAME 0431;ASSIGNOR:SCHULTZ, CLYDE L.;REEL/FRAME:017886/0969 Effective date: 20060705 Owner name: DIRECTCONTACT LLC, MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:RAPIDHEAL LLC;REEL/FRAME:017887/0105 Effective date: 20060227 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |